APC and neoplasm: In our case, NGS findings revealed two APC gene mutations in both the tumor tissue and peripheral blood, which may result in resistance to anti-PD1 therapy. Combined with the factors mentioned above, the tumor immune microenvironment is extremely complex, presenting great challenges in predicting the efficacy of immunotherapy.